SEC Info - Avanos Medical, Inc. - ‘8-K’ for 8/31/20

SEC Info℠

Home

Help

Please Sign In

Avanos Medical, Inc. – ‘8-K’ for 8/31/20

On: Tuesday, 9/1/20, at 8:21am ET · For: 8/31/20 · Accession #: 1606498-20-52 · File #: 1-36440

  As Of               Filer                 Filing    For·On·As Docs:Size

 9/01/20  Avanos Medical, Inc.              8-K:7,9     8/31/20   13:263K

Current Report — Form 8-K
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 8-K         Current Report                                      HTML     31K 
 2: EX-99.1     Miscellaneous Exhibit                               HTML     13K 
 9: R1          Cover                                               HTML     48K 
11: XML         IDEA XML File -- Filing Summary                      XML     12K 
 8: XML         XBRL Instance -- avns-20200831_htm                   XML     23K 
10: EXCEL       IDEA Workbook of Financial Reports                  XLSX      6K 
 4: EX-101.CAL  XBRL Calculations -- avns-20200831_cal               XML      7K 
 5: EX-101.DEF  XBRL Definitions -- avns-20200831_def                XML      9K 
 6: EX-101.LAB  XBRL Labels -- avns-20200831_lab                     XML     70K 
 7: EX-101.PRE  XBRL Presentations -- avns-20200831_pre              XML     35K 
 3: EX-101.SCH  XBRL Schema -- avns-20200831                         XSD     11K 
12: JSON        XBRL Instance as JSON Data -- MetaLinks               12±    18K 
13: ZIP         XBRL Zipped Folder -- 0001606498-20-000052-xbrl      Zip     29K

‘8-K’ — Current Report

This is an HTML Document rendered as filed. [ Alternative Formats ]

iX: C: C:

avns-20200831

i 0001606498 i false i August 31, 202000016064982020-08-312020-08-31

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM i 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report: i August 31, 2020

(Date of earliest event reported)

Commission file number i 001-36440

i AVANOS MEDICAL, INC.

(Exact name of registrant as specified in its charter)

i Delaware

i 46-4987888

(State or other jurisdiction of incorporation)

(I.R.S. Employer Identification No.)

i 5405 Windward Parkway

i Suite 100 South

i Alpharetta,

i Georgia

i 30004

(Address of principal executive offices)

(Zip code)

Registrant’s telephone number, including area code: i (844) i 428-2667

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


i ☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
i ☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
i ☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
i ☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol	Name of exchange on which registered
i Common Stock - $0.01 Par Value	i AVNS	i New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Emerging growth company i ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure

Avanos Medical, Inc. (the “Company”) issued a press release on August 31, 2020, announcing that, effective that same day, Bill Haydon was appointed as Senior Vice President & General Manager – Pain Franchise of the Corporation. A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information presented in Item 7.01 of this Current Report on Form 8-K and Exhibit 99.1 shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, unless the Company specifically states that the information is to be considered “filed” under the Exchange Act or specifically incorporates it by reference into a filing under the Securities Act of 1933, as amended, or the Exchange Act.

Item 9.01 Financial Statements and Exhibits

(d)Exhibits.

The following exhibits are filed with this Current Report on Form 8-K:


Exhibit No.						Description
99.1						Press Release issued by Avanos Medical, Inc. on August 31, 2020
101.SCH						XBRL Taxonomy Extension Schema Document
101.CAL						XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF						XBRL Taxonomy Extension Definition Linkbase Document
101.LAB						XBRL Taxonomy Extension Label Linkbase Document
101.PRE						XBRL Taxonomy Extension Presentation Linkbase Document

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

AVANOS MEDICAL, INC.

Date:

September 1, 2020

By:

/s/ S. Ross Mansbach

S. Ross Mansbach
Vice President, Deputy General Counsel and Corporate Secretary

Dates Referenced Herein and Documents Incorporated by Reference

This ‘8-K’ Filing	Date	Other Filings

Filed on:	9/1/20
For Period end:	8/31/20	3, 4
		List all Filings

↑Top

Filing Submission 0001606498-20-000052 – Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)